Checkpoint Inhibitors in Nonmelanoma Skin Cancer

0.75 CME
0.75 CNE
45 MINS
$0 FEE
SAVE
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Patient exam photo

Overview

Provider Statement

This continuing medical education activity is provided by Vindico Medical Education


Support Statement

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme.

There is no non-commercial support for this activity.

Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its continuing education activities and does not imply ANCC Commission on Accreditation endorsement of any commercial products.


Activity Description

Newly diagnosed cases of non-melanoma skin cancers (NMSCs) are estimated to be more than 3 million cases per year in the United States, with increasing yearly incidence. The majority of new cases are composed of basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC), which are the 2 most common forms of NMSCs. Both BCC and cSCC usually follow an indolent clinical course, and for many, they can be effectively treated with surgery. However, a small proportion of cases will develop advanced disease with significant morbidity and mortality. Historically, patients with advanced disease have had limited treatment options, but recent advances in newer targeted therapies and immune checkpoint inhibitors are providing new options for the treatment of these patients. Within this CME activity, experts in the field review the burden of BCC or cSCC for patients who do not benefit from surgery or radiation and evaluate the latest evidence regarding the use of checkpoint inhibitors for the management of these patients. Furthermore, faculty will discuss strategies to identify patients with cSCC who may benefit from checkpoint inhibitor therapy and examine how checkpoint inhibitors can be incorporated into existing treatment algorithms for patients with advanced BCC.


Target Audience

The intended audience for this activity is oncologists, dermatologists, nurses, and other health care professionals involved in the management of patients with nonmelanoma skin cancer.


Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Review the burden of nonmelanoma skin cancer for patients who cannot benefit surgery or radiation.
  • Evaluate the latest evidence regarding the use of checkpoint inhibitors for patients with BCC or cSCC who may not benefit from surgery or radiation.
  • Outline strategies to identify patients with cSCC who may benefit from checkpoint inhibitor-based therapy.
  • Examine how checkpoint inhibitors may fit into existing treatment algorithms for patients with advanced BCC.

Activity Chair

Karl D. Lewis, MD
Professor of Medicine
Director, Cutaneous Oncology Program
University of Colorado Denver
Denver, CO


Faculty

Ragini Kudchadkar, MD
Associate Professor
Winship Cancer Institute
Emory University
Atlanta, GA

Aleksandar Sekulic, MD, PhD
Deputy Director, Mayo Clinic Cancer Center
Associate Director, Center for Individualized Medicine
Vice Chair, Department of Dermatology
Chair, Cutaneous Oncology Disease Group
Associate Professor of Dermatology
Mayo Clinic Arizona
Scottsdale, AZ


Planners/Reviewers

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Barbara A. Niedz, PhD, RN, CPHQ
Beth Sandy, MSN, CRNP

Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Vindico Medical Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.


Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Vindico Medical Education will provide a maximum of 0.75 contact hours for nurses. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, November 30, 2021, to November 29, 2022.


How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the presentation, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate or contact hour certificate.


Disclosures

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Activity Chair and Faculty report the following relevant relationship(s)

Karl D. Lewis, MD
Consultant: Merck, Pfizer, Regeneron, Sanofi
Independent Research Contractor: Bristol-Myers Squibb, Genentech, Incyte, Iovance, Kartos, Merck, Nektar, OncoSec, Pfizer/Array, Regeneron, Replimune, Seattle Genetics, Senhwa, Ultimovacs

Ragini Kudchadkar, MD
Consultant: Array/Pfizer, Bristol-Myers Squibb, Merck, Regeneron
Independent Research Contractor: Bristol-Myers Squibb, Merck, Regeneron

Aleksandar Sekulic, MD, PhD
No relevant financial relationships to disclose.

Planners/Reviewers report the following relevant relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Barbara A. Niedz, PhD, RN, CPHQ
No relevant financial relationships to disclose.

Beth Sandy, MSN, CRNP
Speaker Contracted by Ineligible Company: Merck, Takeda, AstraZeneca, Jazz, Amgen

Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.


Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.


Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.


CME Questions?

Contact us at cme@vindicoCME.com